We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00718692
First Posted: July 21, 2008
Last Update Posted: October 26, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Swedish Orphan Biovitrum
Information provided by (Responsible Party):
Symphogen A/S
  Purpose
This trial is designed as a multi-centre, single-dose, exploratory dose-finding, open label trial evaluating the safety and efficacy of Sym001 in 4-9 consecutive cohorts. Subjects will receive a single IV dose of Sym001.

Condition Intervention Phase
Immune Thrombocytopenic Purpura Drug: Sym001 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-centre, Single Intravenous Dose, Exploratory Dose-finding, Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP) in RhD Positive, Non-splenectomized Adult Subjects.

Resource links provided by NLM:


Further study details as provided by Symphogen A/S:

Primary Outcome Measures:
  • Incidence and severity of Adverse Events (AEs), including Serious Adverse Events (SAEs) [ Time Frame: 6 weeks post dosing ]

Secondary Outcome Measures:
  • Measurements of platelet counts [ Time Frame: From day 1 through week 6 ]

Enrollment: 61
Study Start Date: July 2008
Study Completion Date: October 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Patients treated with Sym001
Drug: Sym001
Each cohort will receive one single dose of Sym001 according the assigned dose level.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed presence of thrombocytopenia with platelet count < 30,000/mm3 at the pre-dose visit.
  • History of isolated ITP
  • RhD-positive serology.
  • Previous treatment and response to first line therapy for ITP

Exclusion Criteria:

  • Known clinical picture suggestive of other causes of thrombocytopenia, especially systematic lupus erythematosus,antiphospholipid syndrome, Evans syndrome, immunodeficiency states, lymphoproliferative disorders, liver disease,ingestion of drugs such as quinidine/quinine, heparin and sulfonamides and hereditary thrombocytopenia confirmed by relevant laboratory findings.
  • Suspected infection with HIV, Hepatitis C, H. pylori.
  • Clinical splenomegaly
  • History of abnormal bone marrow examination.
  • Ongoing haemorrhage corresponding to a grade 3 or 4 on the WHO bleeding scale.
  • Underlying haemolytic condition
  • History of splenectomy.
  • Subject is pregnant, breast feeding or intends to become pregnant.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00718692


  Show 59 Study Locations
Sponsors and Collaborators
Symphogen A/S
Swedish Orphan Biovitrum
Investigators
Principal Investigator: Mario Von Depka Prondzinski, PD Dr. Werlhoff Institut Hannover, Germany
Principal Investigator: Ann Janssens, Dr. ZU Gasthuisberg, Leuven, Belgium
Principal Investigator: Javier Loscertales Pueyo, Dra Hospital La Princesa, Madrid, Spain
Principal Investigator: Wieslaw Wiktor Jedrzrjczak, Prof. Katedra i klinika Hematologii, Warszawa, Poland
Principal Investigator: Andrei Cucucianu, Dr. Prof. Dr. Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania
Principal Investigator: Marie Scully, Prof. Dr. MD University College London, UK.
  More Information

Publications:
Responsible Party: Symphogen A/S
ClinicalTrials.gov Identifier: NCT00718692     History of Changes
Other Study ID Numbers: Sym001-03
First Submitted: July 18, 2008
First Posted: July 21, 2008
Last Update Posted: October 26, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Symphogen A/S:
Idiopathic
ITP

Additional relevant MeSH terms:
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Blood Coagulation Disorders
Hematologic Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Thrombocytopenia
Blood Platelet Disorders
Immune System Diseases
Hemorrhagic Disorders
Autoimmune Diseases